|1.||Stocchi, Fabrizio: 5 articles (01/2015 - 01/2007)|
|2.||Marconi, Stefano: 3 articles (01/2015 - 07/2010)|
|3.||Huang, Renbin: 2 articles (09/2013 - 02/2012)|
|4.||Liang, Tao: 2 articles (09/2013 - 02/2012)|
|5.||Li, Rong: 2 articles (09/2013 - 02/2012)|
|6.||Yang, Xinxin: 2 articles (01/2012 - 09/2011)|
|7.||Liu, Zhenguo: 2 articles (01/2012 - 09/2011)|
|8.||Cai, Yunpeng: 2 articles (01/2012 - 09/2011)|
|9.||Yuan, Weien: 2 articles (01/2012 - 09/2011)|
|10.||Grassini, Paola: 1 article (01/2015)|
|1.||Parkinson Disease (Parkinson's Disease)
06/01/1991 - "The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease."
04/01/2011 - "Aim of the present study was to evaluate the clinical efficacy, tolerability and quality-of-life measures to melevodopa in advanced Parkinson's disease (PD) with motor fluctuations (MFs). "
01/01/1992 - "Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease."
04/01/1991 - "Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease."
07/01/1987 - "Levodopa methyl ester treatment of Parkinson's disease."
|2.||Amblyopia (Lazy Eye)
02/06/2012 - "Therefore this study assessed the anatomic and physiologic effects of 30 days' treatment of l-dopa methyl ester at different doses on visual cortex area 17 in feline model with amblyopia induced by monocular vision deprivation. "
09/15/2013 - "L-dopa methyl ester attenuates amblyopia-induced neuronal injury in visual cortex of amblyopic cat."
02/06/2012 - "Effects of l-dopa methyl ester on visual cortex injury induced by amblyopia and its underlying mechanism."
02/06/2012 - "The results suggest that l-dopa methyl ester can effectively inhibit amblyopia process via a mechanism that may involve increasing endogenous NGF expression and promoting neural repairment in visual cortex area 17."
|4.||Melanoma (Melanoma, Malignant)
09/15/1988 - "Compounds 1 and 2 exhibited greater potency and selectivity against malignant melanoma than did the natural product L-DOPA methyl ester."
09/15/1988 - "Compound 2 was active in 6 of 10 melanoma and 0 of 5 nonmelanoma cell lines while both Compound 1 and L-DOPA methyl ester were active in 1 of 10 melanomas and 0 of 5 nonmelanomas. "
08/01/1978 - "L-dopa methyl ester has been shown to be an effective antitumor agent against the B-16 melanoma in vivo. "
01/01/1996 - "These results show that in vivo Tyr and Phe restriction improves the therapeutic response of a metastatic variant of B16-BL6 (BL6) murine melanoma to adriamycin (ADR) and B16 melanoma to levodopa methyl ester. "
05/01/1983 - "These data indicate that adding ascorbate and restricting tyrosine and phenylalanine in combination with levodopa methyl ester therapy may become an important strategy for treating malignant melanoma."
09/15/2011 - "Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats."
01/01/2012 - "Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats."
07/01/2010 - "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)."
08/01/1987 - "Complex motor fluctuations and dyskinesias ("on-off" phenomenon) in Parkinson's disease can be corrected by parenteral administration of levodopa, levodopa-methyl-ester, lisuride and apomorphine. "
|1.||levodopa drug combination benserazide
|2.||Levodopa (L Dopa)
|3.||levodopa drug combination carbidopa (Nakom)
|5.||levodopa methyl ester
|10.||Nerve Growth Factor (NGF)